Glycemic management in a patient with type 2 diabetes

New England Journal of Medicine

Volumn 369, Issue 14, 2013, Pages 1370-1372

  Hirsch, Irl B ^a   Molitch, Mark E ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; METFORMIN; SODIUM GLUCOSE COTRANSPORTER 2;

ARTICLE; BLOOD; CASE REPORT; DRUG ANTAGONISM; DRUG COMBINATION; FEMALE; HUMAN; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS;

DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; MIDDLE AGED; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84884966095     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMclde1311497     Document Type: Article

References (10)

1. Patil HR, Al Badarin FJ, Al Shami HA, et al. Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus. Am J Cardiol 2012;110:826-33.
2. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007;9:194-205. (Pubitemid 46206563)
3. Stein SA, Lamos EM, Davis SN. A review of the efficacy and safety of oral antidiabetic drugs. Expert Opin Drug Saf 2013;12:153-75.
4. Nathan DM, Buse JB, Kahn SE, et al. Rationale and design of Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care 2013;36:2254-61.
5. Harja E, Lord J, Skyler JS. An analysis of characteristics of subjects examined for incretin effects on pancreatic pathology. Diabetes Technol Ther 2013;15:609-18.
6. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-79. [Erratum, Diabetes Care 2013;36:490.]
7. Qaseem A, Humphrey LL, Sweet DE, et al. Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2012;156:218-31.
8. Abdul-Ghani MA, Norton L, Defronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev 2011;32:515-31.
9. Rosenstock J, Aggarwal N, Polidori D, et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012;35:1232-8.
10. Vasilakou D, Kargiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes. A systematic review and meta-analysis. Ann Intern Med 2013;159:262-74.